incyte, novartis myelofibrosis trial meets goal
a second pivotal trial of ruxolitinib, developed by incyte corp and novartis, met its goal of showing that the drug significantly reduces spleen size in myelofibrosis patients.
http://feeds.reuters.com/~r/reuters/healthnews/~3/uiaog5ukmja/us-cancer-myelofibrosis-novartis-idustre75320r20110604
33640
04 Jun 2011 20:30:36
reuters
health